Insights and Analysis

Life Sciences and Health Care Horizons Hub

Dive into Our Horizons — your go-to hub for insights, events, and expert perspectives from our global Life Sciences and Health Care team. Stay ahead with the latest trends, challenges, and breakthroughs transforming the industry.

August 2025

In today’s dynamic global environment, life sciences and health care companies are navigating rapid change from evolving regulatory landscapes and policy shifts to technological innovation and growing market complexity. Organizations across the sector are rethinking strategy, mitigating risk, and identifying new opportunities for growth and resilience.

Our Horizons edition brings together insights from across our global Life Sciences and Health Care team to explore the issues and developments shaping the future of the industry. With contributions from lawyers spanning the U.S., Europe, Asia-Pacific, Latin America, and the Middle East, the publication offers practical, forward-looking perspectives on topics impacting companies worldwide.

Our cross-practice approach provides a broad view of emerging trends, whether regulatory, transactional, geopolitical or technological, through the lends of what they mean for businesses operating in this space.

Life Sciences and Health Care Horizons Edition is our firm’s annual publication designed to help clients stay ahead in a constantly evolving sector. We hope you find this year’s insights timely, relevant and thought-provoking.

Introducing the 2025 Horizons edition:

Download:

Horizons 2025 Life Sciences and Health Care Edition

Contacts

Abrams-Steve

location Philadelphia

email Email me

Lynn Mehler

Partner

location Washington, D.C.

email Email me

Jane Summerfield

Partner

location London

email Email me

Upcoming Horizons Events

Boston Horizons: Navigating the political rollercoaster under the Trump Administration

September 2025

Boston Horizons: Navigating the political rollercoaster under the Trump Administration

September 2025

Join us as we discuss the evolving life sciences landscape under the Trump Administration, including drug pricing, FDA restructuring, M&A trends, and the use of AI in clinical trials.

Switzerland Horizons: Staying ahead of the game with Pharma trends

22 October 2025

Switzerland Horizons: Staying ahead of the game with Pharma trends

22 October 2025

Join us in Zurich for our European Life Sciences and Health Care Horizons event — featuring panels on drug pricing, EU Pharma Law, M&A trends, and more. Breakout sessions and a networking reception to follow.

Tokyo Horizons

TBD

Tokyo Horizons

TBD

Horizons highlights

U.S. chapter

What trends will shape U.S. life sciences and health care in 2025?

Our latest Horizons edition explores the key insights shaping what’s next.

Explore what’s ahead:

Post-election regulatory outlook
Real-world data in focus
FDA: What’s next?
Pharmacy access under scrutiny
Drug Supply Chain Security Act: What it means now

Explore the U.S. chapter

AI and Digital Health chapter

What’s next for AI and Digital Health in life sciences and health care?

Discover the latest insights driving the future of AI and Digital Health in our 2025 Horizons edition.

Get a glimpse of what’s next:

AI in health care: What’s next?
Navigating digital health and SaMD regulation
Changes to reimbursement framework
Compliance

Explore the AI and Digital Health Chapter

Cross-jurisdictional chapter

The cross-jurisdictional chapter features the complex regulatory landscape governing clinical trials involving genetically modified organisms (GMOs) in the EU. The piece explores how countries such as Belgium, Germany, Italy, the Netherlands, Spain, and France navigate a patchwork of evolving rules shaped by safety and environmental concerns.

Explore the Cross-jurisdictional chapter

APAC chapter

In the APAC chapter of our 2025 Horizons edition, we highlight “China issues new rules on domestic responsible persons”, which covers the NMPA’s Interim Provisions issued on 13 November 2024 and set to take effect on 1 July 2025. These new rules strengthen regulatory oversight of overseas marketing authorization holders and their appointed domestic responsible persons, who will now share joint responsibility for fulfilling drug marketing authorization obligations and take on a much more prominent, consumer-facing role.

Explore the APAC chapter